UnknownNot Applicable

Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia

France44 participantsStarted 2016-05-03

Plain-language summary

The regions which are assumed to underlie the pathophysiology of schizophrenia, namely hypoactivity at the prefrontal level and pathological hyperactivity of the associative regions of the language located in the left temporoparietal region. To assess the efficacy of tDCS on auditory hallucinations, the investigators performs an randomized double blind versus placebo trial. In each arms patients will receive two tDCS sessions a day during two weeks.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Schizophrenia according to DSM-V. * Refractory auditory hallucinations(despite two antipsychotics trials). * Right-handed patients. * Written informed consent. Exclusion Criteria: * Presence of other psychiatric disorders than schizophrenia (except addiction to tobacco or caffeine ). * History of severe head trauma or coma. * History of epilepsy or neurological disorder or a general medical condition. * Presence of intracranial metallic objects or pacemaker. * Hospitalized patients without consent. * pregnant women .

What they're measuring

auditory hallucinations rating scale (AHRS)

Timeframe: At baseline

auditory hallucinations rating scale (AHRS)

Timeframe: 15 days after

Trial details

NCT IDNCT04352569

SponsorCentre hospitalier de Ville-Evrard, France

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-08

Contact for this trial

Rusheenthira THAVASEELAN, Msc

0143093232 r.thavaseelan@epsve.fr

View on ClinicalTrials.gov More Schizophrenia trials